Sökning: id:"swepub:oai:DiVA.org:umu-221544" >
KRAS G12C-mutant dr...
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
-
- Rosell, Rafael (författare)
- Germans Trias i Pujol Research Institute, Badalona (IGTP), Spain; IOR, Hospital Quiron-Dexeus, Barcelona, Spain
-
- Codony-Servat, Jordi (författare)
- Pangaea Oncology, Hospital Quiron-Dexeus, Barcelona, Spain
-
- González, Jessica (författare)
- Germans Trias i Pujol Research Institute, Badalona (IGTP), Spain
-
visa fler...
-
- Santarpia, Mariacarmela (författare)
- Medical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, Italy
-
- Jain, Anisha (författare)
- Department of Microbiology, JSS Academy of Higher Education & Research, Mysuru, India
-
- Shivamallu, Chandan (författare)
- Department of Biotechnology & Bioinformatics, JSS Academy of Higher Education & Research, Karnataka, Mysuru, India
-
- Wang, Yu (författare)
- Genfleet Therapeutics, Shanghai, China
-
- Giménez-Capitán, Ana (författare)
- Pangaea Oncology, Hospital Quiron-Dexeus, Barcelona, Spain
-
- Molina-Vila, Miguel A. (författare)
- Pangaea Oncology, Hospital Quiron-Dexeus, Barcelona, Spain
-
- Nilsson, R. Jonas A. (författare)
- Umeå universitet,Onkologi
-
- González-Cao, María (författare)
- IOR, Hospital Quiron-Dexeus, Barcelona, Spain
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2024
- 2024
- Engelska.
-
Ingår i: Critical reviews in oncology/hematology. - : Elsevier. - 1040-8428 .- 1879-0461. ; 195
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- KRAS G12C mutations in non-small cell lung cancer (NSCLC) partially respond to KRAS G12C covalent inhibitors. However, early adaptive resistance occurs due to rewiring of signaling pathways, activating receptor tyrosine kinases, primarily EGFR, but also MET and ligands. Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex. Activation of MRAS occurs from alterations in the Scribble and Hippo-dependent pathways, leading to YAP activation. Other mechanisms that involve STAT3 signaling are intertwined with the activation of MRAS. The high-resolution MRAS:SHOC2:PP1C crystallization structure allows in silico analysis for drug development. Activation of MRAS:SHOC2:PP1C is primarily Scribble-driven and downregulated by HUWE1. The reactivation of the MRAS complex is carried out by valosin containing protein (VCP). Exploring these pathways as therapeutic targets and their impact on different chemotherapeutic agents (carboplatin, paclitaxel) is crucial. Comutations in STK11/LKB1 often co-occur with KRAS G12C, jeopardizing the effect of immune checkpoint (anti-PD1/PDL1) inhibitors.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- AQP5
- HUWE1
- Immunotherapy
- KRAS G12C
- MRAS
- NSCLC
- RGS3
- SHOC2
- STK11/LKB1
- VCP
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rosell, Rafael
-
Codony-Servat, J ...
-
González, Jessic ...
-
Santarpia, Maria ...
-
Jain, Anisha
-
Shivamallu, Chan ...
-
visa fler...
-
Wang, Yu
-
Giménez-Capitán, ...
-
Molina-Vila, Mig ...
-
Nilsson, R. Jona ...
-
González-Cao, Ma ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Critical reviews ...
- Av lärosätet
-
Umeå universitet